Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

New England Journal of Medicine ◽

10.1056/nejmoa1109653 ◽

2012 ◽

Vol 366 (6) ◽

pp. 520-529 ◽

Cited By ~ 1687

Author(s):

José Baselga ◽

Mario Campone ◽

Martine Piccart ◽

Howard A. Burris ◽

Hope S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments

SpringerPlus ◽

10.1186/s40064-015-1482-9 ◽

2015 ◽

Vol 4 (1) ◽

Author(s):

Surachat Ngorsuraches ◽

Klangjai Thongkeaw

Keyword(s):

Breast Cancer ◽

Willingness To Pay ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Cancer Treatments ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

PCN59 Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe

Value in Health ◽

10.1016/j.jval.2012.08.1252 ◽

2012 ◽

Vol 15 (7) ◽

pp. A419

Author(s):

F. Andre ◽

N. Marinsek ◽

J.F. Ricci ◽

J. Etchberger ◽

R. Degun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Resource Utilization ◽

Hormone Receptor ◽

Clinical Management ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion

Breast Care ◽

10.1159/000354121 ◽

2013 ◽

Vol 8 (4) ◽

pp. 293-299 ◽

Author(s):

Michael Gnant ◽

Richard Greil ◽

Michael Hubalek ◽

Günther Steger

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Expert Panel ◽

Panel Discussion ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30376-5 ◽

2017 ◽

Vol 18 (7) ◽

pp. 904-916 ◽

Author(s):

José Baselga ◽

Seock-Ah Im ◽

Hiroji Iwata ◽

Javier Cortés ◽

Michele De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2013.01.007 ◽

2013 ◽

Vol 24 (1) ◽

pp. 79-81

Author(s):

S.A. Hurvitz ◽

P.F. Peddi

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Homeopathic supportive care protocol for oral inhibitors of cyclin dependent kinases 4 and 6 (CDK 4/6) in postmenopausal hormone-receptor-positive advanced breast cancer

La Revue d Homéopathie ◽

10.1016/j.revhom.2019.10.006 ◽

2019 ◽

Vol 10 (4) ◽

pp. e69-e73

Author(s):

Jean-Lionel Bagot ◽

Ingrid Theunissen ◽

Jean-Claude Karp ◽

Jean-Philippe Wagner

Keyword(s):

Breast Cancer ◽

Supportive Care ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Cyclin Dependent Kinases ◽

Hormone Receptor Positive ◽

Download Full-text

Faculty Opinions recommendation of Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718493928.793502900 ◽

2015 ◽

Author(s):

Alex Toker ◽

Kristin Brown

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718493928.793497412 ◽

2014 ◽

Author(s):

Larry Norton

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.009 ◽

2012 ◽

Vol 2012 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727683217.793533460 ◽

2017 ◽

Author(s):

Aleix Prat

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text